Familial nephrotic syndrome
MONDO:0002350An instance of nephrotic syndrome that is caused by an inherited modification of the individual's genome.
Also known as: congenital nephrotic syndrome, hereditary nephrotic syndrome
25 clinical trials for this condition and its sub-types, 0 tagged with Familial nephrotic syndrome itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Familial nephrotic syndrome
-
Nephrotic syndrome 14 3 trials
-
Nephrotic syndrome, type 4 1 trial
-
1 sub-type
- Pierson syndrome 0 trials
-
14 sub-types
- Familial idiopathic steroid-resistant nephrotic syndrome with diffuse mesangial proliferation 0 trials
- Familial idiopathic steroid-resistant nephrotic syndrome with diffuse mesangial sclerosis 0 trials
- Familial idiopathic steroid-resistant nephrotic syndrome with minimal changes 0 trials
- Familial steroid-resistant nephrotic syndrome with sensorineural deafness 0 trials
- Focal segmental glomerulosclerosis 1 0 trials
- Nephrotic syndrome, type 10 0 trials
- Nephrotic syndrome, type 11 0 trials
- Nephrotic syndrome, type 12 0 trials
- Nephrotic syndrome, type 13 0 trials
- Nephrotic syndrome, type 2 0 trials
- Nephrotic syndrome, type 3 0 trials
- Nephrotic syndrome, type 6 0 trials
- Nephrotic syndrome, type 8 0 trials
- Nephrotic syndrome, type 9 0 trials
-
Nephrotic syndrome 15 0 trials
-
Nephrotic syndrome 16 0 trials
-
Nephrotic syndrome, IIa 26 0 trials
-
Nephrotic syndrome, type 17 0 trials
-
Nephrotic syndrome, type 18 0 trials
-
Nephrotic syndrome, type 19 0 trials
-
Nephrotic syndrome, type 20 0 trials
-
Nephrotic syndrome, type 21 0 trials
-
Nephrotic syndrome, type 22 0 trials
-
Nephrotic syndrome, type 23 0 trials
-
Nephrotic syndrome, type 24 0 trials
-
New drug aims to stop kidney disease from coming back after transplant
Disease control CompletedThis phase 2 study tested a drug called pegcetacoplan in 13 kidney transplant patients whose original kidney disease (C3G or IC-MPGN) had come back. The goal was to see if the drug could reduce signs of disease activity in the kidney. The study was small and early-stage, so resul…
Phase 2 • Sponsor: Apellis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Hope for rare kidney patients: new drug shows promise in phase 3 trial
Disease control CompletedThis study tested a drug called pegcetacoplan in 124 adults and teens with two rare kidney diseases (C3G and IC-MPGN). The goal was to see if the drug could reduce protein in the urine, a sign of kidney damage. Participants received either the drug or a placebo twice a week for 2…
Phase 3 • Sponsor: Apellis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC